# Windtree Therapeutics Inc /De/ > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Windtree Therapeutics Inc /De/). ## Overview Windtree Therapeutics is a U.S.-based biotechnology company focused on developing therapies for cardiovascular disease, hypertension, and oncology. Its portfolio includes istaroxime, rostafuroxin, preclinical SERCA2a activators, and an aPKCi inhibitor, alongside licensing arrangements and product-candidate partnerships. ## Products & services • Istaroxime for acute heart failure and cardiogenic shock • Rostafuroxin for genetically targeted hypertension • Preclinical SERCA2a activators for heart failure • aPKCi inhibitor programs for oncology • Licensing and partnership out-licenses - **Cardiovascular drug candidates** (45%) — Therapies aimed at acute heart failure, cardiogenic shock, and related cardiovascular conditions. - **Hypertension drug candidates** (15%) — Genetically targeted treatment programs for specific hypertension patient populations. - **Oncology preclinical programs** (15%) — Early-stage inhibitor programs being explored for rare and broad oncology indications. - **Licensing and collaboration revenue** (25%) — Out-licensed programs and partnership arrangements that can generate non-product revenue. - Istaroxime for acute heart failure and cardiogenic shock - Rostafuroxin for genetically targeted hypertension - Preclinical SERCA2a activators for heart failure - aPKCi inhibitor programs for oncology - Licensing and partnership out-licenses ## Customers Windtree’s direct customers are primarily pharmaceutical and biotechnology partners, licensees, and potential acquirers of its development assets rather than a broad consumer base. In a commercialization model, its therapies would ultimately be used by hospitals, physicians, and specialty care providers treating acute cardiovascular disease or oncology patients. The company also seeks partners in specific geographic markets to support development, licensing, and product collaboration. - **Biopharmaceutical partners** (primary) — License or collaborate on drug candidates and development programs to share risk and advance assets. - **Acquisition targets / subsidiary buyers** (primary) — Companies or assets with FDA-approved products that can be acquired to build revenue-generating subsidiaries. - **Healthcare providers** (secondary) — Hospitals and physicians that would use approved cardiovascular therapies in acute care settings. - **Specialty treatment populations** (secondary) — Patients with genetically defined hypertension or oncology indications targeted by specific programs. - Biopharma partners licensing development-stage assets - Potential acquirers of FDA-approved products - Hospitals and clinicians treating acute heart failure - Specialty physicians managing hypertension subgroups - Oncology developers evaluating preclinical assets ## Geography Windtree is headquartered in the United States and operates as a U.S.-based development-stage biotech company. Its disclosures reference potential licensing arrangements and drug product collaborations focused on specified geographic markets, but no country-level revenue breakdown is disclosed in the provided materials. The business is therefore geographically shaped more by partner selection, regulatory pathways, and trial/commercialization locations than by a broad manufacturing footprint. - Headquartered in the United States - Primary operations are U.S.-based R&D and corporate activities - Potential collaborations may target specified geographic markets - No country-level revenue disclosure in provided excerpts - Commercial reach depends on partner licensing and approvals ## Strategy Windtree’s strategy is to advance its cardiovascular and oncology pipeline while building a revenue-generating platform through acquisitions of small companies with FDA-approved products. It also seeks licensing, alliances, and product collaborations to secure capital and broaden commercialization pathways. This approach combines internal development with external asset acquisition to create future operating subsidiaries. - **Advance cardiovascular pipeline assets** (medium-term) — Clinical progress is needed to create value in the core development portfolio. - **Acquire revenue-generating subsidiaries** (short-term) — FDA-approved products can provide commercial revenue while the pipeline matures. - **Secure partnerships and licensing deals** (short-term) — Collaborations can provide funding, market access, and development support. - Advance istaroxime and other pipeline assets - Pursue acquisitions of small companies with FDA-approved products - Use equity to acquire strategic subsidiaries - Expand licensing and alliance-based monetization - Target collaborations in specified geographic markets ## Risks Windtree faces the typical risks of a development-stage biotech company: clinical failure, regulatory setbacks, and uncertainty around commercialization. The company also has specific financing, listing, and asset-valuation risks tied to its capital structure, intangible assets, and dependence on external funding and strategic transactions. - **Going concern and near-term funding risk** [critical] — The company needs additional capital to finance operations and development activities. - **Clinical and regulatory development risk** [high] — Drug candidates may fail in trials or not obtain required approvals. - **Nasdaq listing compliance risk** [high] — Failure to meet continued listing requirements can lead to delisting. - **Intangible asset impairment risk** [high] — IPR&D values depend on future commercial success and development assumptions. - Clinical programs may fail or produce insufficient efficacy/safety - Funding needs are ongoing and external capital is not committed - Nasdaq listing compliance and delisting risk remain material - Intangible assets may be impaired if programs underperform - Partnering and acquisition execution risk could delay strategy ## Accounting Windtree’s most important accounting judgments center on indefinite-lived IPR&D intangible assets, which are tested for impairment using fair value estimates and development assumptions. The company also uses fair value measurements for financing instruments and preferred stock accretion, while going-concern disclosure and delisting-related events can materially affect how investors interpret the financial statements. - **Indefinite-lived IPR&D intangible assets** — Can create material impairment charges if prospects weaken - **Fair value measurement of financing instruments** — Can affect reported earnings and equity balances - **Preferred stock accretion and deemed dividends** — Reduces earnings available to common shareholders - **Going-concern assessment** — Influences disclosure and investor assessment of solvency risk - IPR&D impairment testing depends on success probabilities and cash flow forecasts - Fair value estimates drive reported value of istaroxime and rostafuroxin - Convertible debt and equity instruments can create valuation complexity - Preferred stock accretion affects equity and deemed dividend reporting - Going-concern disclosure signals uncertainty in financial statement assumptions --- *Last updated: 2026-04-29T05:09:37.562271+00:00*